Clinical Trials Logo

Filter by:
NCT ID: NCT00603239 Completed - Clinical trials for Type 2 Diabetes Mellitus

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin

Start date: January 2008
Phase: Phase 3
Study type: Interventional

This study will assess safety and efficacy of exenatide in combination with a thiazolidinedione (TZD) and a TZD plus metformin over 26 weeks in adult patients with type 2 diabetes who have not achieved adequate glycemic control.

NCT ID: NCT00601250 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

Start date: January 2008
Phase: Phase 3
Study type: Interventional

The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in patients with type 2 diabetes mellitus with insufficient glycaemic control

NCT ID: NCT00600886 Active, not recruiting - Acromegaly Clinical Trials

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

Start date: February 2008
Phase: Phase 3
Study type: Interventional

The patients will receive either Pasireotide LAR or Octreotide LAR for one year of treatment. The objective of this study is to compare the proportion of patients with a reduction of mean GH level to <2.5 µg/L and the normalization of IGF-1 to within normal limits (age and sex related) between the two treatment groups (pasireotide LAR and octreotide LAR) at 12 months. Following one year of treatment patients may proceed into the study extension. Patients who did not respond to the treatment they were randomized to (based on month 12 assessment results) will be switched to the other treatment arm at month 13.

NCT ID: NCT00600756 Completed - Clinical trials for Schizophrenic Disorders

Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone

RECOVER
Start date: January 2008
Phase: Phase 3
Study type: Interventional

The trial is designed to assess the long term subjective well-being in schizophrenic outpatients treated with quetiapine XR (extended release) or oral risperidone at flexible dose in a naturalistic setting over a period of one year. Secondary outcome measures have been selected for helping in the differentiation of the compared atypical antipsychotics. The primary objective of this study is to demonstrate the non-inferiority of quetiapine XR to risperidone assessed at month 6 in terms of responder rate using the self-report instrument SWN-K

NCT ID: NCT00600301 Withdrawn - Clinical trials for Diffuse Diabetic Macular Edema

Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study

Start date: January 2008
Phase: Phase 3
Study type: Interventional

Diabetic macular edema is the most common cause of visual loss among patients with diabetic retinopathy. Pars plana vitrectomy has been reported to be effective for the treatment of diabetic macular edema. Previous report showed a limited improvement in visual acuity and macular thickness posterior intraoperative triamcinolone acetonide. Bevacizumab intravitreal injection has been proven be effective in the treatment of diabetic macular edema, in recent publications. The purpose of this study is to evaluate whether vitrectomy with and without intravitreal triamcinolone acetonide and bevacizumab injection affects vision outcome and macular thickness in patients with diabetic macular edema.

NCT ID: NCT00600262 Terminated - Clinical trials for Proliferative Diabetic Retinopathy

Intravitreal Bevacizumab for Diabetic Retinopathy

Start date: December 2005
Phase: Phase 2/Phase 3
Study type: Interventional

Background: to evaluate the 3-month efficacy of a single dose of intravitreal bevacizumab on the progression of severe non proliferative diabetic retinopathy, proliferative diabetic retinopathy and active photocoagulated diabetic proliferative by evaluation of ischemic areas and regression of retinal and disc neovasculrization. Methods: 40 patients were enrolled in a prospective, interventional study. Patients were treated with intravitreal bevacizumab 0.1ml (0.25mg). We evaluated visual acuity, neovascularization leakage points, capillary closure ischemic areas and macular edema by clinical examination and fluorescein angiography. A clinical examination was performed at baseline and days 1,14 and 30. Active leakage points were measured by fluorescein angiography at 30 days.

NCT ID: NCT00600236 Withdrawn - Clinical trials for Diabetes Mellitus Type 2

HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population

Start date: September 2004
Phase: Phase 3
Study type: Interventional

One of the first causes of irreversible blindness in mexican population is diabetic retinopathy which is clearly diferent between patients the time of evolution and development of retinopathy and complications. The aim of this study is to explore the inmunogenetic profile and the influence of HLA in this variations of the sickness to predict the severity of diabetic complications.

NCT ID: NCT00599950 Terminated - Clinical trials for Refractive Disorders

Anterior Stromal Changes After PRK by Using Intraoperative Mitomicin C

Start date: January 2007
Phase: Phase 4
Study type: Interventional

To evaluate the confocal microscopy changes in keratocyte density at the anterior stromal after Photorefractive keratectomy (PRK) surgery, using intraoperative mitomycin C(Mitolem, LEMERY, S.A. de C.V. Mexico D.F. Reg. 136M92 SSA).

NCT ID: NCT00599820 Terminated - Clinical trials for Choroidal Neovascularization

Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

Start date: November 2005
Phase: Phase 3
Study type: Interventional

Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

NCT ID: NCT00599690 Terminated - Corneal Epithelium Clinical Trials

Epi-LASIK : A Confocal Microscopy Analysis of the Corneal Epithelium and Anterior Stroma.

Start date: January 2006
Phase: N/A
Study type: Interventional

To evaluate the confocal microscopy findings at the corneal epithelium and anterior stroma after epi-LASIK Surgery.